Centre and Technology Advisory

Independent guidance for advanced radiation therapy capacity.

Vendor-neutral advisory for hospitals, regions, and operators planning proton, BNCT, or accelerator-based facilities. From feasibility through first patient.

The Path

From site selection to first patient.

FeasibilityTechnologyBuild-outCommissioningFirst patient

Each phase includes structured deliverables. The timeline depends on facility type and regulatory environment.

What It Covers

Five advisory domains, one integrated view.

Feasibility assessment

Population modelling, referral corridor analysis, and realistic patient volume projections for the planned catchment area.

Technology selection

Comparative evaluation of accelerator platforms, beam delivery systems, and shielding requirements. Independent of any single manufacturer.

Treatment planning setup

Workflow design for treatment planning, quality assurance protocols, and integration with existing clinical infrastructure.

Staffing and training

Recruitment strategy, competency frameworks, and training programmes for medical physicists, radiation oncologists, and technologists.

Clinical protocol design

Development of treatment protocols, patient selection criteria, and clinical trial integration where appropriate.

Photo: treatment facility

On Site

Advisory that goes beyond the document.

Where needed, Prof. Sauerwein visits planned or existing facilities to assess infrastructure, observe workflows, and meet clinical teams. Advisory is not only delivered in writing.

Who It Is For

For those building tomorrow's treatment capacity.

Hospitals

University hospitals and cancer centres evaluating advanced radiation therapy infrastructure as part of their long-term clinical strategy.

Regional health ministries

Authorities responsible for healthcare capacity planning who need independent assessment of advanced therapy options for their region.

Operators and investors

Organizations planning or upgrading facilities who require vendor-neutral technical and clinical due diligence before committing capital.

Vendor Neutral

No preferred supplier. Only preferred outcomes.

Prof. Sauerwein has worked with multiple accelerator manufacturers, beam delivery systems, and boron compound developers over four decades. His advisory work draws on direct experience across technology platforms, not commercial alignment with any single vendor.

This independence means recommendations are shaped by what fits the clinical mission, patient population, and operational reality of each specific project.

Start a conversation

Planning a centre? Let us help shape it.

Share your project scope. We will outline how independent advisory can support your planning process.

For the vision behind BNCT deployment, see the BNCT pillar.

Discuss a centre project